Beijing Aosaikang Pharmaceutical Co Ltd

Capital Structure and Liquidity Beijing Aosaikang Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 2.56, indicating that it has more than twice as many current assets as current liabilities. However, the company has a negative net cash position after subtracting total debt, which raises some liquidity concerns. The company's debt-to-equity ratio is very low at 0.01, suggesting a conservative capital structure with minimal reliance on debt financing. ### Profitability and Returns The company's profitability is moderate, with a return on equity (ROE) of 7.36% and a return on assets (ROA) of 5.24%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The company's gross profit margin is 80.15% (1425.72 million CNY gross profit on 1779.03 million CNY revenue), indicating strong cost control in production. However, the operating margin is 14.26% (253.72 million CNY operating income on 1779.03 million CNY revenue), which is lower than the gross margin, suggesting some pressure on operating expenses. ### Segments and Geographic Exposure The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no detailed breakdown of geographic revenue distribution in the provided data, but the company is based in China and likely operates primarily within the domestic market. This concentration may expose the company to regional economic and regulatory risks. ### Growth Trajectory The company's revenue for the latest period is 1.78 billion CNY. While the data does not provide a year-over-year growth rate, the company's operating cash flow of 651.64 million CNY and free cash flow of 85.76 million CNY suggest a stable cash-generating business. The capital expenditure of -143.58 million CNY indicates that the company is not currently investing heavily in new assets, which may limit future growth unless offset by organic expansion or strategic acquisitions. ### Risk Factors The company faces moderate liquidity risk due to its negative net cash position after subtracting total debt. The risk of dilution is low, as the number of shares outstanding is the same for both basic and diluted shares, indicating no significant potential for share dilution. The company's conservative debt structure and strong liquidity position mitigate credit risk, but the negative net cash position introduces some uncertainty. ### Recent Events There are no specific recent events or filings mentioned in the provided data. The company's financial statements are current, but there is no indication of recent strategic moves, regulatory changes, or major business developments.